EP3385256A4 - Procédé de préparation d'une forme cristalline ii d'hydrate eutectique d'un sel trisodique du ahu-377 et du diovan - Google Patents

Procédé de préparation d'une forme cristalline ii d'hydrate eutectique d'un sel trisodique du ahu-377 et du diovan Download PDF

Info

Publication number
EP3385256A4
EP3385256A4 EP16872277.5A EP16872277A EP3385256A4 EP 3385256 A4 EP3385256 A4 EP 3385256A4 EP 16872277 A EP16872277 A EP 16872277A EP 3385256 A4 EP3385256 A4 EP 3385256A4
Authority
EP
European Patent Office
Prior art keywords
diovan
ahu
preparation
crystal form
trisodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16872277.5A
Other languages
German (de)
English (en)
Other versions
EP3385256A1 (fr
EP3385256B1 (fr
Inventor
Minhua Chen
Yanfeng Zhang
Liang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmatech Co Ltd
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Priority to PL16872277T priority Critical patent/PL3385256T3/pl
Publication of EP3385256A1 publication Critical patent/EP3385256A1/fr
Publication of EP3385256A4 publication Critical patent/EP3385256A4/fr
Application granted granted Critical
Publication of EP3385256B1 publication Critical patent/EP3385256B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16872277.5A 2015-12-08 2016-11-10 Procédé de préparation d'une forme cristalline ii d'hydrate eutectique d'un sel trisodique du ahu-377 et du diovan Active EP3385256B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL16872277T PL3385256T3 (pl) 2015-12-08 2016-11-10 Sposób wytwarzania postaci ii krystalicznej eutektycznego hydratu ahu-377 i trisodowej soli diovanu

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510902127.7A CN106854187B (zh) 2015-12-08 2015-12-08 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
PCT/CN2016/105335 WO2017097085A1 (fr) 2015-12-08 2016-11-10 Procédé de préparation d'une forme cristalline ii d'hydrate eutectique d'un sel trisodique du ahu-377 et du diovan

Publications (3)

Publication Number Publication Date
EP3385256A1 EP3385256A1 (fr) 2018-10-10
EP3385256A4 true EP3385256A4 (fr) 2018-12-19
EP3385256B1 EP3385256B1 (fr) 2021-02-24

Family

ID=59013701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16872277.5A Active EP3385256B1 (fr) 2015-12-08 2016-11-10 Procédé de préparation d'une forme cristalline ii d'hydrate eutectique d'un sel trisodique du ahu-377 et du diovan

Country Status (12)

Country Link
US (1) US10442775B2 (fr)
EP (1) EP3385256B1 (fr)
JP (1) JP6628884B2 (fr)
KR (1) KR102070392B1 (fr)
CN (1) CN106854187B (fr)
AU (1) AU2016368863B2 (fr)
CA (1) CA3007864C (fr)
ES (1) ES2862204T3 (fr)
IL (1) IL259871A (fr)
MX (1) MX2018006969A (fr)
PL (1) PL3385256T3 (fr)
WO (1) WO2017097085A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043014T2 (hu) * 2014-12-08 2019-07-29 Crystal Pharmatech Co Ltd Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások
US10857132B2 (en) 2016-10-10 2020-12-08 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
KR102543230B1 (ko) 2019-05-24 2023-06-14 주식회사 파마코스텍 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
CN116646606B (zh) * 2023-07-13 2024-05-03 常州千沐新能源有限公司 一种采用磺酸酯基深共晶溶剂的电解液、制备方法以及锂离子电池

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056546A1 (fr) * 2005-11-09 2007-05-18 Novartis Ag Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep
CN105037289A (zh) * 2015-07-17 2015-11-11 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043014T2 (hu) * 2014-12-08 2019-07-29 Crystal Pharmatech Co Ltd Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056546A1 (fr) * 2005-11-09 2007-05-18 Novartis Ag Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep
CN105037289A (zh) * 2015-07-17 2015-11-11 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017097085A1 *

Also Published As

Publication number Publication date
AU2016368863A1 (en) 2018-07-26
US10442775B2 (en) 2019-10-15
KR20180090346A (ko) 2018-08-10
IL259871A (en) 2018-07-31
CN106854187B (zh) 2020-04-14
US20180354916A1 (en) 2018-12-13
CA3007864C (fr) 2021-03-23
EP3385256A1 (fr) 2018-10-10
AU2016368863B2 (en) 2019-11-14
WO2017097085A1 (fr) 2017-06-15
ES2862204T3 (es) 2021-10-07
CA3007864A1 (fr) 2017-06-15
JP6628884B2 (ja) 2020-01-15
JP2019503999A (ja) 2019-02-14
MX2018006969A (es) 2018-11-29
CN106854187A (zh) 2017-06-16
PL3385256T3 (pl) 2021-09-27
EP3385256B1 (fr) 2021-02-24
KR102070392B1 (ko) 2020-01-28

Similar Documents

Publication Publication Date Title
EP3287444A4 (fr) Nouvelle forme cristalline de sel de méthanesulfonate de lenvatinib et son procédé de préparation
EP3385256A4 (fr) Procédé de préparation d'une forme cristalline ii d'hydrate eutectique d'un sel trisodique du ahu-377 et du diovan
IL255941A (en) Polymorphs of the trisodium salt of scubitril-valsartan
EP3229799A4 (fr) Formes cristallines de complexe supramoléculaire de trisodium comprenant du valsartan et ahu-377 ainsi que procédés associés
EP3393688A4 (fr) Procédé et agencement pour récupération du sel
EP3193876A4 (fr) Formes cristallines d'inhibiteurs de glutaminase
EP3269719A4 (fr) Forme cristalline d'un inhibiteur de jak et son procédé de préparation
IL252691B (en) A method of producing crystals of a diazabicyclooctane derivative and a stable lyophilized preparation
EP3502103A4 (fr) Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation
EP3502100A4 (fr) Forme cristalline d'ozanimod et leur procédé de préparation
HK1256860A1 (zh) 喹唑啉衍生物的晶體及其製備方法
EP3272753A4 (fr) Procédé de préparation de forme cristalline a de pci-32765
EP3239149A4 (fr) Forme cristalline i de la canagliflozine et procédé de préparation de celle-ci
EP3351550A4 (fr) Composé phosphoramidate, procédé de préparation et cristal associé
EP3272751A4 (fr) Forme cristalline de l'ipi-145 et son procédé de préparation
EP3521276A4 (fr) Forme cristalline, forme de sel, et procédé de préparation d'inhibiteur de tyrosine kinase
EP3725786A4 (fr) Forme cristalline et forme de sel d'un inhibiteur de tgf-bri et procédé de préparation correspondant
EP3330267A4 (fr) Sel de dérivé de quinazoline ou cristal associé, et procédé de production de sel de dérivé de quinazoline ou de cristal associé
EP3269710A4 (fr) Cristal de sel de nintedanib diéthanesulfonate, et méthode de préparation et utilisation
SG11201704431VA (en) Novel salt of fused pyrimidine compound and crystal thereof
EP3181573A4 (fr) Cristal de sel de sodium d'acide phosphonique cyclique et son procédé de fabrication
HK1252375A1 (zh) 喹唑啉衍生物的晶體及其製備方法
IL274274A (en) Salt form and crystal form of compound as FGFR4 inhibitor and method of their preparation
ZA202003581B (en) Crystal form of urat1 inhibitor, and preparation method therefor
EP3357925A4 (fr) Composé 4h-pyrazolo-[1,5-alpha]-benzimidazole de type sel et de type cristal, son procédé de préparation et son intermédiaire

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20181115

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 233/47 20060101ALI20181109BHEP

Ipc: C07D 257/04 20060101AFI20181109BHEP

Ipc: C07C 231/24 20060101ALI20181109BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20201006

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1364270

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016053348

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210524

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210525

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210524

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1364270

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2862204

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016053348

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

26N No opposition filed

Effective date: 20211125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211110

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20211130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220701

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220701

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231019

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231215

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231030

Year of fee payment: 8

Ref country code: IT

Payment date: 20231130

Year of fee payment: 8

Ref country code: FR

Payment date: 20231019

Year of fee payment: 8

Ref country code: DE

Payment date: 20231120

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231027

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224